← 返回列表CompanyRudaCure is currently developing the 滴眼液 RCI001 centered around Professor Donghyun Kim (Department of Ophthalmology, 嘉泉大学). Dry eye disease — an uncomfortable condition for the eyes — is viewed as one type of 感觉障碍. The treatment approach involves suppressing the abnormal signal transduction of Rac1, which is associated with the generation of 活性氧 and 炎症反应, to treat 干眼症.
Some 滴眼液 contain substances that stimulate pain nerves, causing discomfort upon 滴眼 — this is a well-known drawback. RCI001 does not stimulate nerves, so it does not cause pain when applied. It also does not produce 眼内压升高, a 副作用 that can lead to glaucoma.
RudaCure is also developing RCI002, a non-narcotic 疼痛治疗药. Since the American Pain Society filed for bankruptcy in 2019 after facing lawsuits for encouraging overprescription of 麻醉性镇痛药, the development of 非麻醉性镇痛药 has become a global priority. RCI002 reduces pain by inhibiting the function of TRPV1, a protein critical to 疼痛信号ing.
RudaCure is a growing company that is actively building partnerships with major 制药公司. ← 返回列表
[医生创业] 即使疼痛也要拥抱——一个充满热情的故事
2022-02-21
Some 滴眼液 contain substances that stimulate pain nerves, causing discomfort upon 滴眼 — this is a well-known drawback. RCI001 does not stimulate nerves, so it does not cause pain when applied. It also does not produce 眼内压升高, a 副作用 that can lead to glaucoma.
RudaCure is also developing RCI002, a non-narcotic 疼痛治疗药. Since the American Pain Society filed for bankruptcy in 2019 after facing lawsuits for encouraging overprescription of 麻醉性镇痛药, the development of 非麻醉性镇痛药 has become a global priority. RCI002 reduces pain by inhibiting the function of TRPV1, a protein critical to 疼痛信号ing.
RudaCure is a growing company that is actively building partnerships with major 制药公司.